[go: up one dir, main page]

AR066265A1 - Compuestos y metodos para mejorar la solubilidad de florfenicol y antibioticos estructuralmente relacionados por medio del uso de ciclodextrinas. composicion. complejo. kit. metodo de tratamiento. - Google Patents

Compuestos y metodos para mejorar la solubilidad de florfenicol y antibioticos estructuralmente relacionados por medio del uso de ciclodextrinas. composicion. complejo. kit. metodo de tratamiento.

Info

Publication number
AR066265A1
AR066265A1 ARP080101709A ARP080101709A AR066265A1 AR 066265 A1 AR066265 A1 AR 066265A1 AR P080101709 A ARP080101709 A AR P080101709A AR P080101709 A ARP080101709 A AR P080101709A AR 066265 A1 AR066265 A1 AR 066265A1
Authority
AR
Argentina
Prior art keywords
composition
florfenicol
water
cyclodextrin
complex
Prior art date
Application number
ARP080101709A
Other languages
English (en)
Original Assignee
Schering Plough Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Plough Ltd filed Critical Schering Plough Ltd
Publication of AR066265A1 publication Critical patent/AR066265A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Reivindicacion 1. Una composicion que comprende: a) de aproximadamente 2,5 a aproximadamente 35% en peso de florfenicol o una sal farmacéuticamente aceptable del mismo; b) de aproximadamente 0,5 a aproximadamente 20% en peso de una ciclodextrina; yc) de aproximadamente 20 a aproximadamente 95% en peso de agua, un solvente y/o una mezcla de los mismos. Reivindicacion 4. La composicion de la reivindicacion 1, donde la ciclodextrina es una ciclodextrina natural, una ciclodextrina modificada, ouna mezcla de las mismas. Reivindicacion 11. La composicion de la reivindicacion 1, donde el solvente se selecciona del grupo que consiste de polietilen glicol 300, polietilen glicol 400, propilen glicol, 2-pirol, n-metil pirol y mezclas de losmismos. Reivindicacion 15. Un método para tratar o prevenir una enfermedad, que comprende: introducir la composicion de la reivindicacion 1 directamente en el agua o en el agua a través de un sistema de tanque de mezcla con dosificador: yadministrar a un sujeto que lo necesita una cantidad terapéuticamente efectiva de un producto que resulta de la introduccion de la composicion en el agua. Reivindicacion 17. Un kit para tratar o prevenir una enfermedad en un sujeto, que comprendela composicion de la reivindicacion 1 e instrucciones para introducir la composicion en el agua para beber que se proporciona al sujeto. Reivindicacion 18. Un complejo de florfenicol que comprende una combinacion intima de florfenicol yciclodextrina preparada al formarse la composicion de la reivindicacion 1 y eliminar el agua, solvente y/o una mezcla de los mismos para formar el complejo.
ARP080101709A 2007-04-27 2008-04-23 Compuestos y metodos para mejorar la solubilidad de florfenicol y antibioticos estructuralmente relacionados por medio del uso de ciclodextrinas. composicion. complejo. kit. metodo de tratamiento. AR066265A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91437607P 2007-04-27 2007-04-27

Publications (1)

Publication Number Publication Date
AR066265A1 true AR066265A1 (es) 2009-08-05

Family

ID=39619330

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101709A AR066265A1 (es) 2007-04-27 2008-04-23 Compuestos y metodos para mejorar la solubilidad de florfenicol y antibioticos estructuralmente relacionados por medio del uso de ciclodextrinas. composicion. complejo. kit. metodo de tratamiento.

Country Status (14)

Country Link
US (1) US20090062397A1 (es)
EP (1) EP2150245A1 (es)
JP (1) JP2010525059A (es)
KR (1) KR20100028537A (es)
CN (1) CN101686956A (es)
AR (1) AR066265A1 (es)
BR (1) BRPI0810601A2 (es)
CA (1) CA2685264A1 (es)
CL (1) CL2008001194A1 (es)
MX (1) MX2009011642A (es)
PE (1) PE20090234A1 (es)
RU (1) RU2009143731A (es)
TW (1) TW200908955A (es)
WO (1) WO2008133901A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY146351A (en) 2003-05-29 2012-08-15 Schering Plough Ltd Compositions for treating infection in cattle and swine
CA2672795A1 (en) * 2006-12-13 2008-06-26 Schering-Plough Ltd. Water-soluble prodrugs of chloramphenicol, thiamphenicol, and analogs thereof
GB2451811A (en) * 2007-08-09 2009-02-18 Ems Sa Delivery composition for solubilising water-insoluble pharmaceutical active ingredients
CN102131772B (zh) * 2008-07-30 2015-03-11 英特威国际有限公司 用作氟苯尼考的中间体的*唑啉-保护的氨基二醇化合物的制备方法
JP5826473B2 (ja) * 2010-09-16 2015-12-02 協和発酵バイオ株式会社 直打用高単位グルコサミン顆粒
CN102160854A (zh) * 2011-04-15 2011-08-24 广东养宝生物制药有限公司 一种包合环糊精的氟苯尼考速释型水溶性粉末制剂及其制备方法
CN102688197A (zh) * 2012-06-07 2012-09-26 湖州爱宝莱动物药业有限公司 一种氟苯尼考水溶颗粒及其制备方法
CN102813627A (zh) * 2012-09-19 2012-12-12 上海同仁药业有限公司 一种氟苯尼考可溶性粉剂的制备方法
CN104667291A (zh) * 2013-12-03 2015-06-03 中牧实业股份有限公司黄冈动物药品厂 一种改进的氟苯尼考包合物的制备方法
CN104800167B (zh) * 2015-04-22 2018-04-10 河南牧翔动物药业有限公司 一种氟苯尼考可溶性粉及其制备方法
CN105055319B (zh) * 2015-07-22 2018-04-10 浙江大飞龙动物保健品有限公司 一种氟苯尼考可溶性粉及其制备方法
CN105079818B (zh) * 2015-08-31 2018-04-20 王玉万 用乙酰胺和环糊精制备氟苯尼考可溶性粉
CN105477642B (zh) * 2015-12-15 2019-08-06 中牧南京动物药业有限公司 一种高生物利用度的氟苯尼考组合物及其制备方法
CN106177983A (zh) * 2016-08-03 2016-12-07 佛山科学技术学院 一种氟苯尼考‑β‑环糊精包合物及其制备方法
CN107519135A (zh) * 2017-09-30 2017-12-29 中牧实业股份有限公司黄冈动物药品厂 一种高水溶型氟苯尼考粉的制备方法
CN109602916A (zh) * 2018-12-13 2019-04-12 广东温氏大华农生物科技有限公司 一种氟苯尼考包合物及其制备方法
CN111374949A (zh) * 2018-12-29 2020-07-07 西安市昌盛动物保健品有限公司 一种氟苯尼考可溶性粉或溶液的制备工艺
CN110279664B (zh) * 2019-07-30 2021-09-03 四川农业大学 一种氟苯尼考包合物冻干粉针剂及其制备方法
CN112535663A (zh) * 2019-09-23 2021-03-23 江西邦诚动物药业有限公司 一种速溶固体分散氟苯尼考粉及其制备方法
CN110787131B (zh) * 2019-12-13 2022-04-01 河北远征药业有限公司 一种氟苯尼考可溶性粉制剂的制备方法
CN112190551A (zh) * 2020-11-20 2021-01-08 湖北龙翔药业科技股份有限公司 一种氟苯尼考可溶性粉及其制备方法
CN112675315A (zh) * 2021-01-05 2021-04-20 佛山科学技术学院 一种γ-环糊精-替米考星包合物及其制备方法和应用
CN112716902B (zh) * 2021-02-04 2021-10-12 广州市和生堂动物药业有限公司 一种氟苯尼考粉及其制备方法
CN112641730A (zh) * 2021-02-19 2021-04-13 山东鲁抗舍里乐药业有限公司高新区分公司 一种可溶氟苯尼考粉的制备方法
CN113230233A (zh) * 2021-05-14 2021-08-10 中国农业科学院兰州畜牧与兽药研究所 一种氟苯尼考固体分散包合微囊及其制备方法与应用
CN114272213B (zh) * 2021-12-28 2023-10-10 厦门惠盈动物药业有限公司 一种氟苯尼考粉及其制备方法
CN114209656B (zh) * 2021-12-31 2023-08-01 浙江金朗博药业有限公司 一种氟苯尼考可溶性粉及其制备方法
CN119385937B (zh) * 2024-11-20 2025-07-15 山东金瑞生物科技有限公司 一种兽用氟苯尼考溶液及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8104203A1 (es) * 1979-02-05 1981-04-16 Schering Corp Un procedimiento para la preparacion de un compuesto d-(treo-1-aril-2-acilamido-3-fluor-1-propanol
IT1173213B (it) * 1984-02-03 1987-06-18 Zambon Spa Procedimento per fluorurare alcuni derivati dall'1l-fenil-2-ammino-1,3-propandiolo e loro intermedi
US5105009A (en) * 1983-06-02 1992-04-14 Zambon S.P.A. Intermediates for the preparation of 1-(phenyl)-1-hydroxy-2-amino-3-fluoropropane derivatives
US5332835A (en) * 1984-02-03 1994-07-26 Zambon S.P.A. Process for fluorinating 1-phenyl-2-amino-1,3-propanediol compounds and new oxazoline compounds useful in this process
US4582918A (en) * 1984-09-19 1986-04-15 Schering Corporation Preparation of intermediates for (threo)-1-aryl-2-acylamido-3-fluoro-1-propanols
US4973750A (en) * 1984-09-19 1990-11-27 Schering Corporation Preparation of (threo)-1-aryl-2-acylamido-3-fluoro-1-propanols
US5227494A (en) * 1988-09-14 1993-07-13 Schering Corporation Process for preparing oxazoline compounds
US4876352A (en) * 1988-09-14 1989-10-24 Schering Corporation Pressurized fluorination of hydroxy alkyl groups
ATE108649T1 (de) * 1990-02-14 1994-08-15 Takeda Chemical Industries Ltd Brausemischung, deren herstellung sowie verwendung.
CA2094810C (en) * 1990-10-25 2002-06-04 Jon E. Clark Process for preparing florfenicol, its analogs and oxazoline intermediates thereto
US5352832A (en) * 1992-12-18 1994-10-04 Schering Corporation Asymmetric process for preparing florfenicol, thiamphenicol chloramphenicol and oxazoline intermediates
US5663361A (en) * 1996-08-19 1997-09-02 Schering Corporation Process for preparing intermediates to florfenicol
GB0205253D0 (en) * 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
US6790867B2 (en) * 2002-05-20 2004-09-14 Schering-Plough Animal Health Corporation Compositions and method for treating infection in cattle and swine
CN1459282A (zh) * 2003-05-29 2003-12-03 季华 水溶性氟苯尼考的生产方法

Also Published As

Publication number Publication date
RU2009143731A (ru) 2011-06-10
WO2008133901A1 (en) 2008-11-06
JP2010525059A (ja) 2010-07-22
BRPI0810601A2 (pt) 2014-10-21
KR20100028537A (ko) 2010-03-12
CA2685264A1 (en) 2008-11-06
PE20090234A1 (es) 2009-04-02
MX2009011642A (es) 2010-01-29
EP2150245A1 (en) 2010-02-10
CL2008001194A1 (es) 2008-11-03
US20090062397A1 (en) 2009-03-05
TW200908955A (en) 2009-03-01
CN101686956A (zh) 2010-03-31

Similar Documents

Publication Publication Date Title
AR066265A1 (es) Compuestos y metodos para mejorar la solubilidad de florfenicol y antibioticos estructuralmente relacionados por medio del uso de ciclodextrinas. composicion. complejo. kit. metodo de tratamiento.
JP2010525059A5 (es)
CL2019002167A1 (es) Compuesto de la fórmula (ic) o una sal farmacéuticamente aceptable del mismo, o una composición farmacéutica que comprende dicho compuesto o una sal farmacéuticamente aceptable del mismo, y al menos un portador farmacéuticamente aceptable, y su uso en el tratamiento de disautonomía familiar al mejorar el empalme de marn. (divisional solicitud 201701823.)
AR059575A1 (es) Metodo para el tratamiento de enfermedades inflamatorias
CA2716874A1 (en) A pharmaceutical composition and its use in the preparation of a medicament for the treatment of cerebrovascular diseases
RU2013121788A (ru) Ингибиторы репликации вич
CO6270302A2 (es) Formulaciones solidas de liberacion rapida que incluyen florfenicol y sales farmaceuticamente aceptables del mismo.
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
AR026122A1 (es) Derivados de 3(5)-amino-pirazol, procedimiento para su preparacion y su uso como agente antitumorales
BRPI0408256A (pt) composto, métodos de tratamento de um humano ou animal, pela limitação da replicação de células, que sofre de cáncer, que sofre de uma doença neoplástica, e que se sofre de doenças proliferativas, uso de um composto, e, processo para a preparação de um composto ou de um seu sal farmaceuticamente aceitável ou de um éster hidrolisável in vivo do mesmo
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
AR073361A1 (es) Combinacion farmaceutica que comprende 3-(-3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico. uso
RU2010137032A (ru) Конъюгаты паклитаксела с полимером и способы лечения рака
CL2012000261A1 (es) Composición farmacéutica líquida de ácido 4- {[9-cloro-7-(2-fluoro-6-metoxifenil)-5h-pirimido[5,4-d][2]benzazepin-2-il]amino}-2-metoxibenzoico en una mezcla de disolventes con al menos 15% de propilenglicol, 15% de peg400 y menos de 50% de agua; y su uso para la preparación de un medicamento para el tratamiento de cáncer.
HRP20150375T1 (hr) Derivati piridazinona
DOP2006000084A (es) Compuestos sulfoximino-macrociclicos y sus sales, composiciones farmaceuticas que comprenden dichos compuestos, metodos de preparacion y usos de los mismos
CL2004000918A1 (es) Compuestos derivados de quinuclidina, antagonistas del receptor muscarinico m3; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para tratar una condicion anti-inflamatoria o alergica, en particular de las vias respiratoria
SI2945620T1 (en) Nitroxyl donors with improved therapeutic index
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
AR082566A1 (es) Formulaciones liquidas de st-246 y metodos relacionados, proceso
AR052221A1 (es) Metodo para el tratamiento de la enfermedad poliquistosis renal
BR112017017211A2 (pt) composto, composição, sal farmaceuticamente aceitável de um composto, combinação, formulação farmacêutica, métodos para matar uma micobactéria e/ou inibir a replicação de micobactérias que causam doença em um animal, para tratamento de uma infecção micobacteriana em um animal e para tratamento de uma doença resultante de uma infecção por micobactéria de um mamífero, e, uso de um composto.
AR062396A1 (es) Uso de derivados de 2,5-dihidroxibenceno para el tratamiento de enfermedades angiogenicas
AR045914A1 (es) Compuesto alcoholico terciario del 8-azoniabiciclo [3.2.1] octano, composicion farmaceutica que lo comprende y su uso para preparar esta ultima

Legal Events

Date Code Title Description
FB Suspension of granting procedure